Obinutuzumab

Last Updated: 02/24/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1113 publications

Polyclonal hypergammaglobulinemia, infiltration of the salivary glands, lymphadenopathy, and kidney damage - Mikulicz's disease, Sjögren's syndrome, or Castleman's disease? Case report and overview of differential diagnosis and treatment.

Polyclonal hypergammaglobulinemia, infiltration of the salivary glands, lymphadenopathy, and kidney damage - Mikulicz's disease, Sjögren's syndrome, or Castleman's disease? Case report and overview of differential diagnosis and treatment.

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti
Published: January 19, 2026

Nephrology : what's new in 2025

Nephrology : what's new in 2025

Journal: Revue medicale suisse
Published: January 16, 2026

Recurrent IgG4-related Tubulointerstitial Nephritis Successfully Treated With Obinutuzumab: A Case Report and Literature Review.

Recurrent IgG4-related Tubulointerstitial Nephritis Successfully Treated With Obinutuzumab: A Case Report and Literature Review.

Journal: Kidney medicine
Published: January 08, 2026

Recent advances in immunosuppressive therapy for lupus nephritis.

Recent advances in immunosuppressive therapy for lupus nephritis.

Journal: Immunological medicine
Published: January 07, 2026

Nephrology highlights in 2025: Diagnostic and therapeutic advances and emerging challenges

Nephrology highlights in 2025: Diagnostic and therapeutic advances and emerging challenges

Journal: Nephrologie & therapeutique
Published: January 06, 2026

Rituximab resistant pemphigus vulgaris successfully treated with obinutuzumab.

Rituximab resistant pemphigus vulgaris successfully treated with obinutuzumab.

Journal: JAAD case reports
Published: December 25, 2025

Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial.

Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial.

Journal: BMJ open
Published: December 25, 2025

Reconsidering the Diagnosis and Management of Obinutuzumab-Induced Acute Thrombocytopenia.

Reconsidering the Diagnosis and Management of Obinutuzumab-Induced Acute Thrombocytopenia.

Journal: Internal medicine (Tokyo, Japan)
Published: December 24, 2025

Borrelia afzelii Hepatitis in Patient Treated with Venetoclax and Obinutuzumab, Switzerland.

Borrelia afzelii Hepatitis in Patient Treated with Venetoclax and Obinutuzumab, Switzerland.

Journal: Emerging infectious diseases
Published: December 11, 2025

Novel Sequential Therapy with Obinutuzumab and Telitacicept in Severe Lupus Nephritis with Glucocorticoid-Induced Avascular Necrosis (AVN) of the Femoral Head: A Case Report.

Novel Sequential Therapy with Obinutuzumab and Telitacicept in Severe Lupus Nephritis with Glucocorticoid-Induced Avascular Necrosis (AVN) of the Femoral Head: A Case Report.

Journal: The American journal of case reports
Published: December 11, 2025

Correction: Obinutuzumab in systemic lupus erythematosus: a real-world experience.

Correction: Obinutuzumab in systemic lupus erythematosus: a real-world experience.

Journal: Frontiers in immunology
Published: December 10, 2025

Spontaneous Resolution of Unexplained Neutropenia in Primary Hyperparathyroidism: A Case Report.

Spontaneous Resolution of Unexplained Neutropenia in Primary Hyperparathyroidism: A Case Report.

Journal: Cureus
Published: November 29, 2025
Showing 1-12 of 1,113

Last Updated: 02/24/2026